Catalent has signed an agreement with Zumutor Biologics to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors. Zumutor develops novel immuno-oncotherapeutics to drive transformational improvements in cancer treatment. ZM008 is a first-in-class monoclonal antibody targeting tumor cell receptors that block natural killer (NK) cell inhibitory signals and enables NK cell activation to generate a potent immune response. ZM008 targets solid tumor cells for diseases such...